FDA — authorised 23 November 2004
- Marketing authorisation holder: BRACCO
- Status: approved
🇺🇸 Multihance in United States
FDA authorised Multihance on 23 November 2004
Marketing authorisations
FDA — authorised 23 November 2004
- Application: NDA021357
- Marketing authorisation holder: BRACCO
- Local brand name: MULTIHANCE
- Indication: INJECTABLE — INTRAVENOUS
- Status: approved
FDA — authorised 23 November 2004
- Application: NDA021358
- Marketing authorisation holder: BRACCO
- Local brand name: MULTIHANCE MULTIPACK
- Indication: INJECTABLE — INTRAVENOUS
- Status: approved
Multihance in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Multihance approved in United States?
Yes. FDA authorised it on 23 November 2004; FDA authorised it on 23 November 2004; FDA authorised it on 23 November 2004.
Who is the marketing authorisation holder for Multihance in United States?
BRACCO holds the US marketing authorisation.